FindTrial
Sign In

Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer

Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048819
Enrollment
Unknown
Registered
2021-07-17
Start date
2018-05-22
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Gold Standard:The DSA examination results were used as the gold standard to compare the accuracy between the two examination methods for the diagnosis of portal vein tumorous emboli and the source of
Index test:magnetic&#32
resonance&#32
imaging&#32
(MRI)&#32
and&#32
contrast-enhanced&#32

Sponsors

Yongtao Yu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
49 Years to 56 Years

Inclusion criteria

Inclusion criteria: 1. patients meeting the diagnostic criteria for PHC; 2. patients with no contraindications to digital subtraction angiography (DSA), CT, or MRI scanning

Exclusion criteria

Exclusion criteria: 1. patients with other malignant tumors; 2. patients with abnormal systemic coagulation or a history of gastrointestinal bleeding; 3. patients with obvious tumor thrombus in the portal veins.

Design outcomes

Primary

MeasureTime frame
Accuracy, sensitivity, and specificity;—

Secondary

MeasureTime frame
Kappa;—

Countries

China

Contacts

Public ContactYongtao Yu

Linyi Central Hospital

2749901187@qq.com+86 15965457331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026